Abstract
Critical limb ischaemia (CLI), due to atherosclerotic arterial occlusion, affects over 20,000 people per year in the United Kingdom with many facing lower limb amputation and early death. A role for endothelin-1 (ET-1) in atherosclerosis is well-established and increased circulating and tissue levels of this peptide have been detected in patients with CLI. ET-1 and its receptors were identified in atherosclerotic popliteal arteries obtained from CLI patients undergoing lower limb amputation. In addition, plasma ET-1 levels were compared with those of non-ischaemic controls. ET-1 was associated with regions of atherosclerotic plaque, particularly in regions with high macrophage content. This peptide was also associated with endothelial cells lining the main vessel lumen as well as adventitial microvessels. ETA and ETB receptors were located within regions of plaque, adventitial microvessels and perivascular nerves. There was a statistically significant increase (P < 0.001) in plasma ET-1 in CLI patients when compared with controls. These results reveal sources of ET-1 in atherosclerotic popliteal arteries that potentially contribute to increased circulating levels of this peptide. Identification of variable receptor distributions in ischaemic tissue suggests a therapeutic potential of selective receptor targeting in patients with CLI.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barst RJ (2007) Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 8:95–109
Cameron NE, Dines KC, Cotter MA (1994) The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats. Diabetologia 37(12):1209–1215
Dashwood MR, Thomas PK (1997) Neurovascular [125I]-ET-1 binding sites on human peripheral nerve. Endothelium 5(2):119–123
Dashwood MR, Timm M, Kaski JC, Murday AJ, Madden BP (1996) [125I]-ET-1 binding to perivascular nerves of human epicardial coronary arteries. Endothelium 4:231–234
Dashwood MR, Timm M, Muddle JR, Ong AC, Tippins JR, Parker R, McManus D, Murday AJ, Madden BP, Kaski JC (1998) Regional variations in endothelin-1 and its receptor subtypes in human coronary vasculature: pathophysiological implications in coronary disease. Endothelium 6(1):61–70
Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65:1336–1340
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr (1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325(14):997–1001
Mangiafico RA, Malatino LS, Santonocito M, Sarnataro F, Dell’Arte S, Messina R, Santangelo B (1999) Plasma endothelin-1 levels in patients with peripheral arterial occlusive disease at different Fontaine’s stages. Panminerva Med 41(1):22–26
Newton DJ, Khan F, McLaren M, Kennedy G, Belch JJ (2005) Endothelin-1 levels predict 3-year survival in patients who have amputation for critical limb ischaemia. Br J Surg 92(11):1377–1381
Remuzzi G, Benigni A (1993) Endothelins in the control of cardiovascular and renal function. Lancet 342:589–593
Rubanyi GM, Polokoff MA (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46(3):325–415
Schroeder TV (2007) The TASC II– Inter-Society Consensus for management of peripheral arterial disease. Eur J Vasc Endovasc Surg 33(Suppl 1):S1–76
Second European Consensus Document on chronic critical limb ischaemia (1991) Circulation 82(4 Suppl):IV1-26.
Tsui JC, Dashwood MR (2005) A role for endothelin-1 in peripheral vascular disease. Curr Vasc Pharmacol 3(4):325–332
Tsui JC, Baker DM, Biecker E, Shaw S, Dashwood MR (2002) Potential role of endothelin 1 in ischaemia-induced angiogenesis in critical leg ischaemia. Br J Surg 89:741–747
Yasuda M, Kohno M, Tahara A, Itagane H, Toda I, Akioka K, Teragaki M, Oku H, Takeuchi K, Takeda T (1990) Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J 119(4):801–806
Zeiher AM, Goebel H, Schächinger V, Ihling C (1995) Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 91(4):941–947
Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M (1992) Increased plasma endothelin-1 in acute ischemic stroke. Stroke 23(7):1014–1016
Acknowledgement
We wish to thank Dr Khin Thway for expert assessment of immunostained material.
MRD acknowledges the continued support from the Department of Clinical Biochemistry, Royal Free Hospital.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dashwood, M.R., Tsui, J.C.S. Further evidence for a role of endothelin-1 (ET-1) in critical limb ischaemia. J. Cell Commun. Signal. 5, 45–49 (2011). https://doi.org/10.1007/s12079-010-0109-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-010-0109-8